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Simone Windho¨vel1, Anita L. Hufnagel3, Roland Houben1,5 and Svenja Meierjohann3,5
A large proportion of human melanomas harbor a mutation leading to permanent activation of the serine/
threonine kinase BRAF, and as a consequence, they have developed dependence on BRAF/mitogen-activated
protein kinase signaling. Accordingly, BRAF inhibitors such as Vemurafenib show a good anti-tumorigenic effect
on metastases with the BRAFV600E mutation. Although an initial period of sustained tumor regression is usually
observed after Vemurafenib treatment, tumors often relapse at the same site, and apoptosis induction of
melanoma cells in vitro is incomplete. Here, we demonstrate, using a large panel of melanoma cell lines, that
Vemurafenib induces features of stress-induced senescence in addition to apoptosis. This senescence phenotype
is characterized by heterochromatin formation, changes in cell shape, and increased senescence-associated
b-galactosidase activity. Importantly, senescence features induced by BRAFV600E inhibition was also detected in
human melanoma cells xenografted into nude mice. Our observations provide a possible explanation for the lack
of complete and durable pro-apoptotic effect of Vemurafenib in patients.
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INTRODUCTION
Patients with metastatic melanoma have a poor prognosis
and only limited therapeutic options are available (Miller and
Mihm, Jr, 2006; Garbe et al., 2011). However, the identification
of oncogenic BRAF in the majority of melanomas and the demon-
stration that BRAF mutant melanoma cells are largely dependent
on BRAF/mitogen-activated protein kinase (MAPK) signaling have
been important findings with high pharmacological impact
(Puzanov and Flaherty, 2010). More than 80% of these BRAF
mutations lead to a valine to glutamate exchange at position 600,
rendering the protein permanently active by releasing an intra-
molecular inhibitory interaction (Davies et al., 2002). Therefore,
specific BRAFV600E inhibitors such as Vemurafenib (PLX4032) are
beneficial to a large proportion of melanoma patients (Puzanov
and Flaherty, 2010). The overall response rate of patients with
BRAFV600E-positive melanomas to Vemurafenib is roughly 50%
and responsive patients display significant tumor regression and
prolonged survival (Chapman et al., 2011). Although the strategy
of inhibiting mutant BRAF is the most successful melanoma
treatment option so far, in most cases, the initial phase of tumor
regression is followed by Vemurafenib resistance, disease relapse,
and death of the patients (Aplin et al., 2011; Chapman et al.,
2011). Consequently, the elucidation of resistance mechanisms is
a highly investigated area and has revealed the involvement of
CRAF, AKT, receptor tyrosine kinases, and BRAF amplifications or
splice variants in BRAF inhibitor resistance (Fedorenko et al.,
2011). To better understand and improve BRAF inhibitor therapy,
it is also crucial to evaluate the phenotypic cellular responses and
thereby the extent of apoptosis versus cell cycle arrest initiated by
Vemurafenib.
BRAF signaling can have different effects on cells of
melanocyte origin. On the one hand, BRAF activation in
primary melanocytes in vitro induces an irreversible growth
arrest termed senescence, which is regarded as a major tumor
suppressor mechanism (Michaloglou et al., 2005). Senescence
is triggered by a variety of cellular stresses, such as telomere
attrition, UV exposure, reactive oxygen stress or—as in case of
BRAFV600E expression—oncogene activation (oncogene-
induced senescence; Ogrunc and d’Adda di Fagagna, 2011).
In contrast to quiescent cells, senescent cells can be arrested
in G0/G1 or G2/M and develop a characteristic flat and/or
multinuclear phenotype. Benign melanocytic nevi, which
frequently harbor oncogenic BRAF mutations, remain stably
growth arrested for decades and display markers of oncogene-
induced senescence, such as an increased activity of the
acidic b-galactosidase and induction of the tumor suppressor
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p16 (Michaloglou et al., 2005). Therefore, it has been
suggested that benign nevi are an in vivo example of
oncogene-induced senescence, and overcoming senescence
is regarded as a key step in the progression to melanoma.
However, the presence of senescent nevus cells remains
controversial (Cotter et al., 2007; Gray-Schopfer et al., 2008;
Michaloglou et al., 2008; Tran et al., 2012).
On the other hand, in BRAF-mutant melanoma, BRAF is
essential for tumor survival and proliferation. BRAF signaling is
involved in preventing apoptosis—e.g., by shifting the balance
between pro- and anti-apoptotic proteins in the direction of
the latter—and in cell cycle progression—e.g., by inducing the
transcription of cyclin D and by suppressing cell cycle-
inhibitory proteins, which are also relevant for mediating
senescence (Balmanno and Cook, 2009). Vemurafenib
treatment of melanoma cell lines was associated with a pro-
apoptotic response (Lee et al., 2010; Sondergaard et al., 2010;
Tap et al., 2010), the preferred outcome of tumor therapy.
However, in other tumor types, the inhibition of the driver
oncogene also promoted senescence. For instance, non-small-
cell lung cancer cells treated with EGFR or MAPK/extracellular
signal–regulated (ERK) kinase inhibitors (Hotta et al., 2007;
Wang et al., 2011) and colorectal cancer cells treated with
vascular endothelial growth factor receptor 2 inhibitors
underwent cellular senescence (Hasan et al., 2011).
Here, we investigated the effect of Vemurafenib on apop-
tosis and senescence in a series of human melanoma cell lines.
RESULTS
To determine the response of melanoma cells to BRAF
inhibition, we used a panel of 14 melanoma cell lines: 10
carried the BRAFV600E mutation, 1 harbored the BRAFV600K
mutation, and 3 expressed wild-type BRAF. Seven of the
BRAFV600E mutant cell lines are well-characterized lines from
the NCI-60 panel (http://discover.nci.nih.gov/cellminer/muta-
tionGeneLoad.do). The cells were treated with 0.5mM Vemur-
afenib, a concentration previously demonstrated to effectively
inhibit ERK1/2 signaling in BRAFV600E-mutant cells (Joseph
et al., 2010), and cell cycle distribution was analyzed by flow
cytometry. After 2 days of treatment, the M14 cell line
responded by undergoing cell death in 15% of the cell
population, but the proportion of dead cells decreased after
prolonged Vemurafenib exposure (Figure 1a). In the BRAF-
mutant Malme 3M cell line, cell death was induced in a
delayed manner and did not start before 4 days of Vemur-
afenib exposure (Supplementary Figure S1a online). However,
in M14 and Malme 3M cells, an increased proportion of the
surviving cells was found in G0/G1 after 7 days of Vemur-
afenib treatment (Figure 1a and Supplementary Figure S1a
online). Most cell lines showed a clear increase in the
proportion of G0/G1 cells in response to Vemurafenib, but
no evidence of cell death (Supplementary Figure 1b online).
As a control, we included the melanoma cell line WMM1175,
which expresses inducible p16 and can be triggered into
senescence by addition of isopropyl-b-D-thiogalactopyrano-
side (Haferkamp et al., 2008). Again, p16 expression caused
accumulation of cells in G0/G1 (Supplementary Figure S1b
online). Unexpectedly, the two BRAF-mutant melanoma cell
lines LOX IMVI and RPMI 7951 showed no alteration of cell
cycle phases in response to Vemurafenib. We also examined
the proliferation behavior of several melanoma cell lines by
performing carboxyfluorescein diacetate retention analyses.
Here, cells are labeled with carboxyfluorescein diacetate,
which is diluted out of proliferating cells over time but largely
retained in non-proliferating cells. Figure 1c shows that the
degree of label retention of the melanoma cell lines in
response to Vemurafenib is comparable with the label reten-
tion in WMM1175 cells after 5 days of isopropyl-b-D-thioga-
lactopyranoside-induced p16 expression, which drives the
cells into the senescence program.
As expected, all BRAF-mutant melanoma cell lines that
responded to Vemurafenib showed diminished MAPK
activity, as detected by reduced P-ERK1/2 levels (Figure 2).
In addition, they also displayed diminished the accumula-
tion of P-Rb, a marker of cell cycle arrest (Figure 2). LOX
IMVI cells, which showed no reduction of P-ERK1/2 in
response to Vemurafenib, displayed no reduction of P-Rb. In
RPMI 7951 cells, reduction of P-ERK1/2 as well as P-Rb was
noted in response to Vemurafenib, despite a lacking effect on
the cell cycle.
To investigate the long-term effects of Vemurafenib, we
treated the cell lines with the drug for 7 days. In many of the
cell lines that previously showed an increase in G0/G1,
namely M19-Mel, SK-MEL-28, UACC-62, UACC-257, and
FM88, we observed a characteristic change in cell shape to
an enlarged and flattened phenotype, which is reminiscent of
senescence (Supplementary Figure S2 online). Some of the
enlarged cells were binucleated or multinucleated (Figure 3a,
b). This phenotype was never observed in the cell lines
expressing wild-type BRAF, but only in cell lines carrying
mutated BRAF. All cells displaying an enlarged phenotype
showed increased senescence-associated b-galactosidase
(SA-b-Gal) activity, supporting the notion that Vemurafenib
can induce senescence features in BRAF-dependent mela-
noma cell lines (Figure 3c). In addition, cell lines without
obvious cell shape alterations such as M14, Malme 3M, and
Mel2a also showed increased SA-b-Gal staining (Figure 3d).
The accumulation of nuclear heterochromatin and promyelo-
cytic leukemia (PML)-positive nuclear bodies often accompa-
nies senescence (Narita et al., 2003; Courtois-Cox et al.,
2008), and trimethylated H3K9 (H3K9me3) as well as PML
are well-established markers for these structures (Krauss, 2008;
Vernier et al., 2011). We first analyzed the protein amount of
PML and H3K9me3 in untreated and Vemurafenib-treated
melanoma cells (Figure 4a). An increase of either one of these
markers or both of them was observed in those cell lines that
showed SA-b-Gal staining in more than 10% of the cell
population in response to Vemurafenib (compare Figures 3d
and 4a). We also performed immunofluorescence staining of
PML in nine of the BRAF mutant cell lines and found that the
results concurred with our western blot data (Figure 4b and
Supplementary Figure S3 online). All these data gained from
in vitro analyses of the melanoma cell lines are summarized in
Supplementary Table S1 online.
The tumor suppressor protein p16 is an important regulator
of senescence in response to different cellular stress signals.
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However, p16 is frequently inactivated in melanoma, and
germline p16 mutations predispose to this cancer type
(Castellano et al., 1997; Sharpless and Chin, 2003). In line
with these data, p16 expression was only detectable in two
cell lines (SK-MEL-28 and Mel2a). Unexpectedly, it was even
downregulated in the presence of Vemurafenib, suggesting
that the observed decreased Rb phosphorylation is not
mediated by p16 (Supplementary Figure S4 online).
To establish whether growth inhibition of Vemurafenib-
treated cells was irreversible, as characteristic for senescent as
opposed to quiescent cells, we investigated the colony
formation capacity of those cells that display Vemurafenib-
dependent senescence features and included control cells,
which do not display senescence features (MDA-MB-435,
RPMI 7951, Mel Juso). Following 5 days of Vemurafenib
treatment, cells were washed to remove media with drug, and
equal numbers of control- or Vemurafenib-treated cells were
seeded at low density and cultivated for 8 and 9 days in the
absence of the inhibitor. Colony formation was then mon-
itored by crystal violet staining. Except M19-Mel and Mel2a,
all cell lines that display Vemurafenib-dependent senescence
features showed reduced capacity to form colonies, reaching
significance in case of Malme 3M, SK-MEL-28, UACC-62, and
FM88 (Figure 5a, b). In particular, the colony-forming capacity
of SK-MEL-28 cells was reduced by 480% (Figure 5a, b).
Here, the colonies formed by Vemurafenib pretreated SK-
MEL-28 cells were much smaller than their counterparts from
the control population. In addition, many enlarged single
cells, having obviously not undergone cell division after
removal of Vemurafenib, were detectable (Figure 5a). The
colony-forming capacity of the control cells RPMI 7951 and
Mel Juso were not affected by Vemurafenib pretreatment
(Figure 5b). Curiously, in M19 Mel and MD-MBA 435 cells,
Vemurafenib pretreatment even led to enhanced colony
formation, although this did not reach statistical significance
(Figure 5b).
Control
300
G1
Sub–
G1
Sub–
G1S +
G2/M
S +
G2/M200
100
0
300
G1
Sub–
G1
S +
G2/M Sub–
G1
S +
G2/M
G1 G1
200
100
0
0 1,023
300
200
100
0
300
100%
80%
60%
40%
20%
0%
200
100
0
0 1,023 0 2 4 70 1,0230
Control 2 d Vem 4 d Vem 7 d Vem
M19-Mel
1,023
2 d Vem 4 d Vem 7 d Vem Sub G1 S
G2/MG0/G1
M14
100%
80%
60%
40%
20%
0%
0 2 4 7
Sub G1 S
G2/MG0/G1300
G1
Sub–
G1
S +
G2/M
G1
Sub–
G1
S +
G2/M
G1
G1
Sub–
G1
Sub–
G1
S +
G2/M
S +
G2/M
200
100
0
300
200
100
0
0
200
300 250
200
150
100
50
0
250
200
150
100
50
0
100 101 102 103 104
100 101 102 103 104
Co
un
t
M14
250
200
150
100
50
0
180
160
140
120
100
80
60
40
20
0
100 101 102 103 104
100
CFDA fluorescence CFDA fluorescence
102 103 104101
WMM1175 M19-Mel
180
160
140
120
100
80
60
40
Co
un
t
Co
un
t
Co
un
t
Co
un
t
Co
un
t
20
0
250
200
150
100
50
0
100 101 102 103 104
100
CFDA fluorescence
CFDA fluorescence CFDA fluorescence CFDA fluorescence
Malme-3M UACC-62 FM88
101 102 103 104
1,023 0 1,023 0 1,023
300
200
100
0
300
200
100
0
0 1,023
Figure 1. Apoptosis and G1 accumulation in response to BRAFV600E inhibition. (a) Left: Cell cycle profile of M14 cells treated with the solvent DMSO or with
0.5mM Vemurafenib (Vem) for 2, 4, and 7 days (d). Medium and inhibitor were changed every second day. Right: Bar graph representation, including standard
deviations, of the cell cycle profiles of M14 cells after indicated times of Vem treatment. (b) Left: Cell cycle profile of M19-Mel cells under the same conditions as
described in a. Right: Bar graph representation, including standard deviations, of the M19-Mel cell cycle profile after indicated times of Vem treatment. FACS
analyses were repeated twice, and the presented profiles are representative. Data are mean values from three independent experiments. (c) Flow cytometry analysis
of carboxyfluorescein diacetate (CFDA)-labeled cells. The histogram plot on day 0 is displayed in green. The blue and red lines represent the histogram plots of the
CFDA fluorescence, following 6 days in the absence and presence of 0.5mM Vem or 4 mM isopropyl-b-D-thiogalactopyranoside (WMM1175), respectively.
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To confirm these data in an independent assay, we
performed SA-b-Gal staining of those cell lines that displayed
significantly reduced colony formation in Figure 5b as well as
MDA-MB-435 cells as control. Nine days after withdrawal of
Vemurafenib, the percentage of SA-b-Gal-positive cells was
still increased compared with control cells in SK-MEL-28,
UACC-62, and FM88 cells (Figure 5c). Owing to the high SA-
b-Gal background staining of Malme 3M cells, a difference
could not be detected here. Altogether, we could show that
the senescence-inducing effect of Vemurafenib is sustainable
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Figure 2. ERK1/2 inhibition and Rb dephosphorylation by Vemurafenib (Vem). Western blot analysis of the indicated melanoma cell lines after 48 h of treatment
with the solvent DMSO (—) or 0.5mM Vem. Cell lysates were analyzed for the expression of phospho-Rb (Ser 780), total Rb, phospho-ERK1/2 (Thr 202/Tyr 204),
and total ERK1/2.
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Figure 3. Appearance of senescent cells in response to BRAFV600E inhibition. (a) Phase contrast images of indicated cell lines after 7 days of control (Ctrl; DMSO)
or Vemurafenib (Vem) treatment (0.5mM). Red arrows indicate binucleated or multinucleated cells, bars¼ 20mm. (b) Quantification of binucleated and
multinuclead cells after Vem treatment in percent. (c) Senescence-associated b-galactosidase (SA-b-Gal) staining of indicated cell lines after 7 days of control
(DMSO) or Vem treatment (0.5mM), bars¼ 20mm. (d) Quantification of SA-b-Gal-positive cells after Vem treatment in percent. (e) SA-b-Gal staining of M14, SK-
MEL-28, and UACC-62 cells after 7 days of control (DMSO) or Vem treatment with indicated concentrations. The percentage of SA-b-Gal-positive cells in each
cell population is indicated, bar¼ 20mm. Data shown are derived from three independent experiments. Standard deviations are indicated. *Po0.05, **Po0.001
(Student’s t-test, two-tailed, paired).
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in some cell lines even after drug release. As only a fraction of
the cell population (between 20% and 85%, see Figure 3d)
becomes senescent because of the Vemurafenib treatment, the
percentage of terminally arrested senescent cells in a cell
population naturally decreases with time, dependent on the
cell cycle duration of the unaffected cells. It is possible that the
consequential expansion and colony formation of unaffected
cells leads to the underestimation of the fraction of terminally
arrested and senescent cells at the beginning of drug
withdrawal.
To determine whether an increase in Vemurafenib concen-
tration affects the degree of apoptosis and senescence induc-
tion, we selected nine BRAFV600E-positive cell lines and
treated them with 2 and 5mM of the inhibitor in addition to
the previously used 0.5mM. Compared with 0.5mM, 2 and 5mM
Vemurafenib led to a slightly stronger inhibition of P-ERK1/2 in
some, but not all cell lines (Supplementary Figure S5 online).
In concordance with the data shown above, LOX IMVI cells
were irresponsive to Vemurafenib irrespective of the applied
concentration. To analyze the effect of the increased Vemur-
afenib concentration on cell growth and death, we monitored
cellular density in the absence or presence of the inhibitor
over a 5-day period using the X-celligence system (Roche;
Supplementary Figure S6a). This assay allows detection of the
impedance or electric resistance of the cell population, which
usually correlates with cell density: while cell growth leads
to an increasing cell index, cell death is represented by a
decreasing cell index. Because of their round cell shape,
LOX IMVI cells are not suitable for this kind of analysis and
were therefore omitted. In most cell lines, 2 and 5mM
Vemurafenib decreased cell density compared with 0.5mM,
indicating that the inhibitor is capable of inducing predomi-
nantly cell death instead of senescence at higher concentra-
tions. In case of M19-Mel and UACC-62, addition of
Vemurafenib first led to an increase of cell index, which can
be attributed to the strongly increased cell shape that
also influences impedance (see Supplementary Figures S2
and S6 online). Thus, we complemented these data with a
BrdU incorporation analysis, showing the extent of viable
and proliferating cells, as well as detection of dead cells by
flow cytometry (Supplementary Figure S6b and S7a online).
Both assays also demonstrated that increased Vemurafenib
concentrations had an enhanced effect on the cells. In most
cell lines, induction of cell death went along with increases in
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Figure 4. Vemurafenib causes the generation of heterochromatin and promyelocytic leukemia (PML) bodies in some melanoma cell lines. (a) Western blot
analysis of the indicated melanoma cell lines after 48 h of treatment with the solvent DMSO (control) or 0.5mM Vemurafenib (Vem). Cell lysates were analyzed for
the expression of PML and trimethylated histone H3 (H3K9me3). b-Actin served as loading control. (b) Immunofluorescence showing focal nuclear accumulation
of PML in indicated melanoma cell lines. Whole cells are depicted in phase contrast images, and the nuclei are visualized by 4’,6-diamidino-2-phenylindole
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the pro-apoptotic protein PUMA, thus indicating cell death by
apoptosis (Supplementary Figure S7b online).
However, even though 2 and 5mM Vemurafenib concen-
trations led to a stronger apoptosis response compared
with 0.5mM, we found that many of the surviving cells
displayed senescence features such as flattened cell shape
and positive SA-b-Gal staining, which was visible in up to
80% of the cell population (Figure 3e and Supplementary
Figure S8 online).
To exclude that senescence induction upon BRAF inhibition
is an in vitro artifact, we analyzed the effect of Vemurafenib in
a mouse model. Tumors were induced in Nude mice
(Hsd:Athymic Nude-Foxn1nu) by subcutaneous injection of
SK-MEL-28 cells. After the tumors had reached a size of
approximately 150 mm3, the animals were treated by daily
intraperitoneal administration of 25 mg Vemurafenib per kg
body weight. This led to initial tumor regression (Figure 6a).
Control animals received the same volume of the solvent
Miglyol 812, and here tumors continued growing. Tumors
were excised following 7 days of treatment when tumor
regression was evident in all Vemurafenib-treated mice (day
25 after start of the experiment). In accordance with the
in vitro data, the tumor cells of inhibitor-treated mice
displayed increased SA-b-Gal activity compared with the
control tumors (Figure 6b). In addition, we could observe a
decrease of the proliferation marker Ki67, a slight, but
nonsignificant increase of PML and H3K9me3, and the
occasional appearance of multinucleated cells in tumors from
Vemurafenib-treated mice. An increase of apoptosis, mea-
sured by cleaved caspase 3 and TUNEL, was not noted.
However, as tumor regression was rather prominent immedi-
ately after the addition of Vemurafenib (Figure 6a), apoptosis
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has most likely taken place earlier and was not detectable
anymore at the time of tumor excision.
DISCUSSION
Aberrant activation of BRAF in primary melanocytes and
fibroblasts induces permanent cell cycle arrest through onco-
gene-induced senescence (Michaloglou et al., 2005). Here we
show that the induction of senescence is also an important
response to BRAF inhibition in BRAFV600E and BRAFV600K -
mutant melanoma cells. In this respect, we demonstrate that
out of nine BRAF mutant cell lines that respond with cell cycle
arrest to Vemurafenib treatment, eight display at least two
markers of senescence-like typical changes in cell size and
shape, increased SA-b-Gal activity, or H3K9me3-positive
heterochromatic foci and PML bodies (see Supplementary
Table S1 online). In the cell line LOX IMVI, Vemurafenib did
not affect ERK1/2 phosphorylation at all, indicating that the
reason for BRAF inhibitor resistance is likely found upstream
of ERK1/2. Possible mechanisms for such a phenomenon
include enhanced receptor tyrosine kinase signaling, the
development of BRAF splice mutants, or mutations in the
kinase COT1, all of which can overcome the inhibitory effect
of Vemurafenib on ERK1/2 (Johannessen et al., 2010;
Villanueva et al., 2010; Poulikakos et al., 2011).
Most melanoma cells rely on an activated MAPK pathway,
which is most often triggered by oncogenic BRAFV600E. RAF
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Figure 6. Shrinkage of xenotransplanted tumors in mice treated with Vemurafenib (Vem) is associated with the induction of senescence-associated
b-galactosidase (SA-b-Gal) activity. In 12 nude mice, two tumors each were induced by subcutaneous injection of SK-MEL 28 cells. After 18 days, when the
tumors reached a volume of around 150 mm3 (indicated by arrow), the animals received intraperitoneal injections of either phosphate-buffered saline/DMSO or
Vemurafenib (25 mg kg1). (a) Tumor growth curve of control (Cont)-treated and Vem-treated cells. Tumor size was measured and relative mean values
(±standard deviation) are displayed. (b) Senescence and apoptosis markers in xenotransplanted tumors after 7 days of treatment (day 25 after tumor cell injection).
Tumors were analyzed for the appearance of senescence markers, namely, multinucleated cells (MNCs), increased SA-b-Gal activity, and the expression of PML,
trimethylated histone H3 (H3K9me3), and the proliferation marker Ki67. Apoptotic cells were detected using TUNEL assay and immunohistochemical staining of
cleaved caspase 3 (Cleav. casp). Cell counts of each marker (including standard deviations) are shown in the histogram and correspond to the mean count number
of three different tumors of each group (bar (20 )¼200mm, bar (100 )¼ 10mm). PML, promyelocytic leukemia.
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proteins phosphorylate and activate MAPK/ERK kinase, and
MAPK/ERK kinase activates the ERK 1 and 2, which target
more than 70 different substrates in different subcellular
compartments (Chen et al., 2001). ERK1/2 can exert their
pro-tumorigenic function through different mechanisms.
ERK1/2-dependent phosphorylation of the transcription
factor FOXO3a leads to its proteasomal degradation, thus
resulting in the reduced expression of the FOXO3a-dependent
expression of pro-apoptotic Bcl-2-like protein 11 (Balmanno
and Cook, 2009). Notably, pro-apoptotic PUMA is also
induced by FOXO3a, and might therefore be indirectly
regulated by ERK1/2 (You et al., 2006). In addition, direct
Bcl-2-like protein 11 and Bcl-2-associated death phosphory-
lation by ERK1/2 reduces protein stability or prevents binding
of anti-apoptotic proteins, respectively, thereby shifting the
balance between pro- and anti-apoptotic proteins in favor of
cell survival. However, the cyclin-dependent kinase inhibitor
gene CDKN1B (encoding p27KIP1) is another target gene of
FOXO3a, which is blocked by ERK1/2. In addition, cell cycle-
promoting genes such as CCND1 (cyclin D1) and c-MYC are
induced by this pathway (Kerkhoff et al., 1998; Ciuffreda
et al., 2009). Interestingly, small interfering RNA-mediated
downregulation of the ERK1/2 target gene c-MYC in
established melanoma cells results in senescence (Zhuang
et al., 2008). Thus, next to anti-apoptosis, proliferation is a
major function of the ERK1/2 pathway in tumors.
The effect of Vemurafenib on melanoma cells expressing
the BRAFV600E oncogene, the main activator of the ERK1/2
pathway in melanoma, is generally described as pro-apoptotic
(Lee et al., 2010; Tap et al., 2010; Qin et al., 2012). Although
we could confirm this effect, in particular, when we used high
concentrations of Vemurafenib, we found that a substantial
proportion of surviving cells displays features of senescence.
These data demonstrate that apoptosis and senescence
response do not exclude each other in a cell population.
Although apoptosis induction is the preferred effect of drug
treatment in cancer, senescence is also considered an eligible
treatment objective (Acosta and Gil, 2012). It is known that
senescence triggers a local immune response, which helps to
clear the tumor mass (Chien et al., 2011). As nude mice still
possess natural killer cells, which reportedly display anti-
melanoma activity, the observed tumor regression can be
easily explained. However, senescent cells can also provide a
microenvironment that increases the metastatic abilities of
neighboring cells (Ohanna et al., 2011), and might thereby
contribute to resistance. Furthermore, cancer cells that were
driven into senescence by chemotherapeutic agents can
develop chemoresistant side populations with cancer stem
cell-like properties (Achuthan et al., 2011). BRAF has a role in
regulating mitosis, and BRAF inhibition impairs spindle
formation and leads to chromosomal missegregation in HeLa
cells (Borysova et al., 2008). Similar events might take place in
Vemurafenib-treated melanoma cells, with the risk of causing
increased genomic instability and selection for drug-resistant
cells with more aggressive tumorigenic phenotypes. The
involvement of senescence in melanoma regression and
resistance in Vemurafenib-treated patients will be the subject
of our future studies.
MATERIALS AND METHODS
Cell culture
Human melanoma cell lines LOX IMVI, M14, M19-Mel, Malme 3M,
MDA-MB-435, RPMI 7951, SK-MEL-28, UACC-62, and UACC-257
were cultivated in DMEM and FM88, Mel2A, Wu¨Mel45, M26, and
Mel Juso in RPMI-1640. For all cell lines, the medium was
supplemented with 10% fetal calf serum, penicillin (100 U ml 1,
Gibco, Darmstadt, Germany), and streptomycin (100mg ml 1,
Gibco). The WMM1175 cells have been described previously
(Becker et al., 2001). For induction of p16, 4 mM isopropyl-b-D-
thiogalactopyranoside was added to the culture medium.
SA-b-Gal staining
Cells were either left untreated or were treated with indicated
concentrations of Vemurafenib for 7 days, unless specified otherwise,
before being washed with phosphate-buffered saline (PBS; pH 7.2)
and fixed with 3.7% formaldehyde in PBS (pH 7.2) for 5 min at room
temperature. After rinsing the cells with PBS (pH 7.2), they were
subjected to b-Gal assay as described elsewhere (Dimri et al., 1995)
and then examined by light microscopy.
Cell lysis and immunoblot analysis
Attached and floating cells were harvested, rinsed twice with PBS,
and were analyzed by western blot analysis as specified in the
Supplemental information online.
Immunofluorescence
Cells were seeded on glass coverslips, treated for the indicated times
with 0.5mM Vemurafenib, and were fixed for 5 min at 4 1C in 100%
methanol, followed by a permeabilization step in 100% acetone
at 4 1C. Cells were then blocked with 1% bovine serum albumin
and probed with anti-PML antibody (1:100; PG-M3; Santa Cruz
Biotechnology, Santa Cruz, CA). Alexa Fluor 594 goat-anti-mouse
(Invitrogen, Darmstadt, Germany) was used as secondary antibody.
Nuclear counterstaining was performed with 4’,6-diamidino-2-
phenylindole.
Flow cytometry
Cells were treated with 0.5, 2, and 5mM Vemurafenib or the solvent
DMSO alone. After indicated timespans, attached cells and floating
cells in the medium supernatant were harvested and fixed in 70%
ethanol. Details of the analysis are given in the Supplemental Material
section.
Xenotransplantation
For tumor induction, SK-MEL-28 was injected subcutaneously into
each lateral flank of 6-week-old female nude mice. When the
tumors reached a volume of around 150 mm3, mice were randomly
divided into a vehicle control group and a Vemurafenib
treatment group, as specifed in the Supplemental Materials section
in detail. All the animal experiments were approved by the local
authorities (government of Unterfranken) according to the legal
requirements.
Immunohistochemistry
Three-micrometer sections of formalin-fixed and paraffin-embedded
tumors were treated and stained as described previously (Houben
et al., 2012; see also Supplementary Materials online).
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